Is there a role for all-trans retinoic acid in combination with recombinant erythropoetin in myelodysplastic syndromes? A report on 59 cases

Leukemia

Volumn 23, Issue 4, 2009, Pages 673-678

  Itzykson, R ^a,b   Ayari, S ^b,c   Vassilief, D ^b,d   Berger, E ^b,e   Slama, B ^b,f   Vey, N ^b,g   Suarez, F ^h   Beyne Rauzy, O ^b,i   Guerci, A ^b,j   Cheze, S ^b,k   Thomas, X ^b,l   Stamatoullas, A ^b,m   Gardembas, M ^b,n   Bauduer, F ^b,o   Kolb, A ^b,p   Chaury, M C ^b,q   Legros, L ^b,r   Damaj, G ^b,s   Chermat, F ^b   Dreyfus, F ^b,d   Fenaux, P ^a,b,t   Ades, L ^a,b,t   more..

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b Groupe Francophone des Myelodysplasies (GFM)   (France)

^c NANTES UNIVERSITY HOSPITAL   (France)

^d AP HP ^*  (France)

^e DIJON UNIVERSITY HOSPITAL   (France)

^f hôpital d'Avignon   (France)

^g INSTITUT PAOLI CALMETTES   (France)

^h HÔPITAL NECKER ENFANTS MALADES   (France)

ⁱ CHU PURPAN   (France)

^j UNIVERSITY HOSPITAL OF NANCY   (France)

^k CHU Clemenceau   (France)

^l EDOUARD HERRIOT HOSPITAL   (France)

^m ROUEN UNIVERSITY HOSPITAL   (France)

ⁿ ANGERS UNIVERSITY HOSPITAL   (France)

^o CENTRE HOSPITALIER DE LA CÔTE BASQUE   (France)

^p REIMS UNIVERSITY HOSPITAL   (France)

^q LIMOGES UNIVERSITY HOSPITAL   (France)

^r CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^s AMIENS UNIVERSITY HOSPITAL   (France)

^t INSTITUT GUSTAVE ROUSSY   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; ERYTHROPOIETIN; RECOMBINANT ERYTHROPOIETIN; RETINOIC ACID;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLAST CELL; BONE MARROW CELL; BONE PAIN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOPENIA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRY SKIN; ERYTHROCYTE TRANSFUSION; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HORMONE BLOOD LEVEL; HUMAN; HYPERCALCEMIA; INFECTION; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; MUCOSAL DRYNESS; MULTICENTER STUDY; MYALGIA; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; NEUTROPHIL COUNT; PAIN; PRIORITY JOURNAL; RELAPSE; SIDE EFFECT; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 64849101837     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2008.362     Document Type: Article

References (36)

1. Hellstrom-Lindberg E, Malcovati L. Supportive care, growth factors, and new therapies in myelodysplastic syndromes. Blood Rev 2008; 22 75-91.
2. Steensma DP, Tefferi A. Anemia in the elderly: How should we define it, when does it matter, and what can be done? Mayo Clin Proc 2007; 82: 958-966.
3. Malcovati L. Impact of transfusion dependency and secondary iron overload on the survival of patients with myelodysplastic syndromes. Leuk Res 2007; 31 (Suppl 3): S2-S6.
4. Casadevall N, Durieux P, Dubois S, Hemery F, Lepage E, Quarre MC et al. Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: A randomized, controlled trial. Blood 2004; 104: 321-327.
5. Jadersten M, Montgomery SM, Dybedal I, Porwit-MacDonald A, Hellstrom-Lindberg E. Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF. Blood 2005; 106: 803-811.
6. Negrin RS, Stein R, Vardiman J, Doherty K, Cornwell J, Krantz S et al Treatment of the anemia of myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor in combination with erythropoietin. Blood 1993; 82: 737-743.
7. Hellstrom-Lindberg E, Gulbrandsen N, Lindberg G, Ahlgren T, Dahl IM, Dybedal I et al. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: Significant effects on quality of life. Br J Haematol 2003; 120: 1037-1046.
8. Park S, Grabar S, Kelaidi C, Beyne-Rauzy O, Picard F, Bardet V et al Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: The GFM experience. Blood 2008; 111: 574-582.
9. Kelaidi C, Eclache V, Fenaux P. The role of lenalidomide in the management of myelodysplasia with del 5q. Br J Haematol 2008; 140: 267-278.
10. Evans T. Regulation of hematopoiesis by retinoid signaling. Exp Hematol 2005; 33: 1055-1061.
11. Aul C, Runde V, Gattermann N. All-trans retinoic acid in patients with myelodysplastic syndromes: Results of a pilot study. Blood 1993; 82: 2967-2974.
12. Koeffler HP, Heitjan D, Mertelsmann R, Kolitz JE, Schulman P, Itri L et al. Randomized study of 13-cis retinoic acid v placebo in the myelodysplastic disorders. Blood 1988; 71: 703-708.
13. Kurzrock R, Estey E, Talpaz M. All-trans retinoic acid: Tolerance and biologic effects in myelodysplastic syndrome. J Clin Oncol 1993; 11: 1489-1495.
14. Ohno R, Naoe T, Hirano M, Kobayashi M, Hirai H, Tubaki K et al. Treatment of myelodysplastic syndromes with all-trans retinoic acid. Leukemia Study Group of the Ministry of Health and Welfare. Blood 1993; 81: 1152-1154.
15. Kuendgen A, Strupp C, Aivado M, Bernhardt A, Hildebrandt B, Haas R et al. Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. Blood 2004; 104: 1266-1269.
16. Pilatrino C, Cilloni D, Messa E, Morotti A, Giugliano E, Pautasso M et al. Increase in platelet count in older, poor-risk patients with acute myeloid leukemia or myelodysplastic syndrome treated with valproic acid and all-trans retinoic acid. Cancer 2005; 104: 101-109.
17. Hofmann WK, Ganser A, Seipelt G, Ottmann OG, Zander C, Geissler G et al. Treatment of patients with low-risk myelodysplastic syndromes using a combination of all-trans retinoic acid, interferon alpha, and granulocyte colony-stimulating factor. Ann Hematol 1999; 78 125-130.
18. Giagounidis AA, Haase S, Germing U, Schlegelberger B, Wilkens L, Busche G et al. Treatment of myelodysplastic syndrome with isolated del(5q) including bands q31-q33 with a combination of all-trans retinoic acid and tocopherol-alpha: A phase II study. Ann Hematol 2005; 84: 389-394.
19. Zhang W, Zhou F, Cao X, Cheng Y, He A, Liu J et al. Successful treatment of primary refractory anemia with a combination regimen of all-trans retinoic acid, calcitriol, and androgen. Leuk Res 2006; 30: 935-942.
20. Smith MA, Parkinson DR, Cheson BD, Friedman MA. Retinoids in cancer therapy. J Clin Oncol 1992; 10: 839-864.
21. Stasi R, Brunetti M, Terzoli E, Amadori S. Sustained response to recombinant human erythropoietin and intermittent all-trans retinoic acid in patients with myelodysplastic syndromes. Blood 2002; 99: 1578-1584.
22. Ganser A, Maurer A, Contzen C, Seipelt G, Ottmann OG, Schadeck-Gressel C et al. Improved multilineage response of hematopoiesis in patients with myelodysplastic syndromes to a combination therapy with all- trans-retinoic acid, granulocyte colony-stimulating factor, erythropoietin and alpha-tocopherol. Ann Hematol 1996; 72: 237-244.
23. Cheson BD, Bennett JM, Kantarjian H, Pinto A, Schiffer CA, Nimer SD et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000; 96 3671-3674.
24. Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006; 108: 419-425.
25. Tamburini J, Elie C, Park S, Beyne-Rauzy O, Gardembas M, Berthou C et al. Effectiveness and tolerance of low to very low dose thalidomide in low-risk myelodysplastic syndromes. Leuk Res 2008, [e-pub ahead of print].
26. Raza A, Reeves JA, Feldman EJ, Dewald GW, Bennett JM, Deeg HJ et al Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood 2008; 111: 86-93.
27. Lyons RM, Cosgriff T, Modi S, McIntyre H, Fernando I, Backstrom J et al. Results of the Initial Treatment Phase of a Study of Three Alternative Dosing Schedules of Azacitidine (Vidaza(R)) in Patients with Myelodysplastic Syndromes (MDS). Blood 2007; 111: 819.
28. Sloand EM, Wu CO, Greenberg P, Young N, Barrett J. Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. J Clin Oncol 2008; 26: 2505-2511.
29. Balleari E, Rossi E, Clavio M, Congiu A, Gobbi M, Grosso M et al. Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: Results from a randomized single-centre study. Ann Hematol 2006; 85: 174-180.
30. Hellstrom-Lindberg E, Ahlgren T, Beguin Y, Carlsson M, Carneskog J, Dahl IM et al. Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: Results from a randomized phase II study and long-term follow-up of 71 patients. Blood 1998; 92: 68-75.
31. Musto P, Falcone A, Carotenuto M, Catalano L, Cennamo A, Rotoli B. Granulocyte colony-stimulating factor and erythropoietin for the anemia of myelodysplastic syndromes: A real improvement with respect to erythropoietin alone? Blood 1994; 84: 1687-1688.
32. Remacha AF, Arrizabalaga B, Villegas A, Manteiga R, Calvo T, Julia A et al. Erythropoietin plus granulocyte colony-stimulating factor in the treatment of myelodysplastic syndromes. Identification of a subgroup of responders. The Spanish Erythropathology Group. Haematologica 1999; 84: 1058-1064.
33. Stasi R, Pagano A, Terzoli E, Amadori S. Recombinant human granulocyte-macrophage colony-stimulating factor plus erythropoietin for the treatment of cytopenias in patients with myelodysplastic syndromes. Br J Haematol 1999; 105: 141-148.
34. Maurer AB, Ganser A, Seipelt G, Ottmann OG, Mentzel U, Geissler GR et al. Changes in erythroid progenitor cell and accessory cell compartments in patients with myelodysplastic syndromes during treatment with all-trans retinoic acid and haemopoietic growth factors. Br J Haemaitol 1995; 89: 449-456.
35. Tehranchi R, Fadeel B, Schmidt-Mende J, Forsblom AM, Emanuelsson E, Jadersten M et al. Antiapoptotic role of growth factors in the myelodysplastic syndromes: Concordance between in vitro and in vivo observations. Clin Cancer Res 2005; 11: 6291-6299.
36. Schmidt-Mende J, Gogvadze V, Hellstrom-Lindberg E, Zhivotovsky B. Early mitochondrial alterations in ATRA-induced cell death. Cell death and differentiation 2006; 13: 119-128.